MSH2 and cancer: Overall, a total of 21 mutation carriers of MSH2 pathogenic variants resulted from cascade testing of three families (18 alive mutation carriers, and three dead obligate carriers) were identified; 14 cases were cancer affected [one case with both endometrial cancer (EC) and CRC] (Table 2).